>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:

  • AXSM +13.1%, TTD +10.5%, COTY +6.7%, HLIO +6.1%, VTRS +5.4%, RETA +5%, PRVA +3.9%, TSEM +2.8%, VAC +2.6%, EDIT +2.4%, USFD +1.3%, BKI +1%, .

Other news:

  • AUTL +27.3% (Blackstone (BX) to invest up to $250 mln in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia)
  • RDHL +7.5% (RedHill Biopharma and South Korea's Kukbo Co. announce a strategic investment of up to $10 million in RedHill)
  • BBIG +6.5% (filed Form 10 registration statement in connection with the planned spin-off of its subsidiary Cryptyde)
  • ENDP +4.2% (signs agreement with Premier to supply VASOSTRICT)
  • ELMS +4% (intention to move ahead with plans to launch the Urban Utility vehicle after the ELMS Board approved production)
  • MTL +3.3% (reports supplying ~22,000 tonnes of rails and other steel rolls for construction of Moscow Metro's Bolshaya Koltsevaya Line)
  • CMMB +3.3% (announced that Donald R. Marvin has been named Chief Financial Officer, Executive Vice President and Chief Operating Officer)
  • EXP +2% (files mixed securities shelf offering )
  • REGN +1.9% (reports new Phase 3 data for REGEN-COV showing long-term protection against COVID-19)
  • HVT +1.8% (authorizes special cash dividend, also approves new $25 mln share repurchase authorization)
  • KALV +1.8% (presents data demonstrating KVD900 achieves rapid exposure and improves outcomes as oral on-demand treatment of HAE)
  • CSIQ +1.6% (awarded 52 MWp for the solar PV project Caracoli in the recent public auction by Colombia's Ministry of Energy)
  • ASTR +1.5% (files application with FCC requesting authority to launch and operate satellite system)
  • WRB +1.3% (declares special cash dividend of $1.00/share)
  • GOL +1.1% (reports October traffic results)
  • TEVA +1% (presents AJOVY data)

Analyst comments:

  • ACEL +3.6% (upgraded to Buy from Hold at Deutsche Bank)
  • BTRS +3.1% (upgraded to Overweight from Neutral at JP Morgan)
  • ACMR +2.3% (upgraded to Buy from Hold at The Benchmark Company)
  • APPN +2.2% (upgraded to Buy from Hold at Truist)
  • AVB +1.3% (upgraded to Overweight from Equal-Weight at Morgan Stanley)